Favorable leukemia- free survival (LFS) for adults and children undergoing myeloablative umbilical cord blood (UCB) transplantation with cyclophosphamide (CY), fludarabine (FLU) and total body irradiation (TBI): a single center analysis of 194 patients. Blood. 2008;112:A1957....
and perhaps even a survival advantage, physicians outside Germany hesitate to recommend escBEACOPP because of toxicity concerns. Acute hematologic toxicity is high with escBEACOPP, with grade 3 to 4 infections occurring in 22% of patients. Acute myeloid leukemia (AML) developed in 3% of patien...
RegisterLog in Sign up with one click: Facebook Twitter Google Share on Facebook event-free survival Failure-free survival Oncology The timespan that follows therapy for a malignancy or other dread disease, during which there are no objective signs of recurrence ...
Dr Halwani reported receiving grants from AbbVie, Pharmacyclics, Genentech, Kyowa Kirin LLS, and the Leukemia and Lymphoma Society outside the submitted work. No other disclosures were reported. Funding/Support: Funding for this study was provided by Bayer US, LLC. Role of the Funder/Sponsor:...
2021 Minimal Residual Disease in Acute Myeloid Leukemia JAMA Oncology Invited Commentary December 1, 2020 See More About Oncology Hematology Hematologic Cancer Leukemias Trending Contemporary Management of Acute Myeloid Leukemia JAMA Oncology Review August 8, 2024 Home Time in Older Adults With AML JAMA ...
Acute myeloid leukemia (AML) is a genetically heterogeneous blood disorder. AML patients are associated with a relatively poor overall survival. The objective of this study was to establish a machine learning model to accurately perform the prognosis prediction in AML patients. Methods We first screen...
In adults with previously treated, high-risk chronic lymphocytic leukemia, treatment with acalabrutinib was found to be non-inferior to treatment with ibrutinib in terms of progression-free survival, meeting the primary end point of the phase 3 ELEVATE-RR clinical trial. ...
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Most patients in both groups had acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or MDS (79% vs. 66%). Multiple myeloma accounted for 11% of patients aged ≥ 60 and 18% of younger patients. Other diseases included chronic lymphocytic leukemia (n = 2 vs. 0), ...
Anat Gafter-Gvili, in Leukemia Research, 2018 Highlights • SLE patients are at increased risk for lymphoma compared to general population. • The most common lymphoma subtype is a diffuse large B cell lymphoma. • Pathogenesis is not clear. • Data regarding lymphoma survival and outcome...